fashion -WSS

fashion

author：focus 2025-09-27 21:54:54 - browse：3

Purple AML cells in blood flow — coverage from STAT — Acute myeloid leukemia cells amid blood flow. Adobe

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy.

While the label means that physicians will have to have a conversation about secondary malignancies occurring after Carvykti treatment, oncologists and CAR-T experts said the label update won’t change anything about the use of Carvykti.

“I do not believe this particular change will have any bearing on patient care,” said Saad Usmani, a myeloma physician and cell therapist at Memorial Sloan Kettering who has also studied Carvykti. That’s partly because physicians already discuss the risk of second cancers due to other cancer therapies including radiation, some targeted therapies, and some chemotherapies, which are necessary in the use of CAR-T. “We do have secondary primary malignancy discussions with patients in the context of transplant and will have to do for CAR-T as well,” Usmani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Intarcia’s device

hotspot

WSS

Emergency workers more likely to restrain Black patients: study

Thermo Fisher plant for manufacturing gene therapies to expand

How Vertex's cystic fibrosis drug is changing patients' lives

Biotech stock slump in 2023: awaiting the turnaround

Second xenotransplant done with gene

CDC advisers recommend seasonal use of Pfizer RSV shot

focus

fashion

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Supreme Court strikes down use of affirmative action

Intarcia’s device

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Dobbs anniversary: the lost opportunity of abortion as health care

Thermo Fisher plant for manufacturing gene therapies to expand

Drug repurposing or repositioning? The language matters

How AI helped researchers track recovery from depression

explore

STAT Virtual Event: Putting AI to the Test

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Readout Newsletter: XBI biotech index, Akero Therapeutics

What Congress can do to address the rural doctor shortage

Why are Kaiser Permanente staff considering a strike?

Maker of FluMist seeks to allow at

hotspot

knowledge

Wikipedia

explore